ARCHIVED: Immatics and MD Anderson announce launch of Immatics US, Inc., to develop multiple T-cell and TCR-based adoptive cellular therapies
Company to be based in Houston with first round funding of $60 million
MD Anderson News Release 08/26/2015
Immatics Biotechnologies GmbH (Immatics) and The University of Texas MD Anderson Cancer Center announced today the launch of Immatics US, Inc., a new company aiming at becoming a global leader in adoptive cellular therapies (ACT) for the treatment of a range of tumor types.
Immatics believes that...
ARCHIVED: MD Anderson to host evening fun run supporting skin cancer research
MD Anderson News Release 08/26/2015
Runners and walkers will soon hit the streets for the eighth annual AIM for the CURE Melanoma...
ARCHIVED: Internationally recognized leader to direct Moon Shots Program prevention efforts
MD Anderson News Release 08/26/2015
The University of Texas MD Anderson Cancer Center has appointed former U.S. Public Health Service...
ARCHIVED: Generic heart medication shown to prolong ovarian cancer patients’ survival
Even despite prognostic factors and co-morbidities associated with poorer outcomes
MD Anderson News Release 08/23/2015
In a first-of-its-kind study, researchers demonstrate a benefit in overall survival among epithelial ovarian cancer (EOC) patients receiving generic heart medications known as beta-blockers. Survival was shown to be greatest among those prescribed first-generation nonselective beta-blockers. According...
ARCHIVED: MD Anderson to build new outpatient center in West Houston
MD Anderson News Release 08/20/2015
With the approval of The University of Texas System Board of Regents today, The University of Texas...
ARCHIVED: UTMB, MD Anderson to collaborate on League City campus
MD Anderson News Release 08/20/2015
The University of Texas Medical Branch at Galveston and The University of Texas MD Anderson Cancer...
ARCHIVED: MD Anderson study reveals new insight into tumor progression
Regulation of tumor ‘microenvironment’ may offer alternate approach for treatment
MD Anderson News Release 08/17/2015
ARCHIVED: Merck and MD Anderson announce immuno-oncology research collaboration in solid tumors
Clinical trials to evaluate Merck’s KEYTRUDA® (pembrolizumab) in combination with other medicines and treatments across multiple tumor types...
ARCHIVED: Helping preschoolers deploy ‘superpowers’ against sunburn
Ray and the Sunbeatables™ debut through CATCH; arise from MD Anderson research
MD Anderson News Release 08/12/2015
Five...
ARCHIVED: MD Anderson names Valerae O. Lewis, M.D., chair of Orthopaedic Oncology
Dr. Lewis is internationally recognized for her expertise in pelvic sarcoma surgery and substantial contributions in shaping orthopaedic education...
ARCHIVED: Poor survival among colorectal cancer patients tied to biomarker CSN6
MD Anderson News Release 08/10/2015
A protein called CSN6 has been found to be correlated with poor survival among patients...
ARCHIVED: Shorter course of radiation therapy associated with less toxicity, improved quality of life in women with early stage breast cancer
MD Anderson researchers recommend hypofractionated treatment as a starting point for treatment discussion between patients, physicians...
ARCHIVED: Potential new therapy approaches to reverse kidney damage identified
Study shows that cell plasticity program resulting from kidney damage can be targeted to reverse disease and fibrosis.
MD Anderson...
ARCHIVED: MD Anderson study reveals new insight into DNA Repair
The enzyme fumarase key to reversing genetic damage leading to cancer and therapy resistance
MD Anderson News Release 08/03/2015<...